COLUCID PHARMACEUTICALS, INC. (CLCD) financial statements (2021 and earlier)

Company profile

Business Address 222 THIRD STREET
CAMBRIDGE, MA 02142
State of Incorp.
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments100405165698035
Cash and cash equivalents84142328368035
Short-term investments1727283733  
Prepaid expense 111210
Other undisclosed current assets1      
Total current assets:101415265718135
Noncurrent Assets
Long-term investments and receivables 23 5  
Long-term investments 23 5  
Deferred costs      1
Other noncurrent assets0000000
Total noncurrent assets:0230501
TOTAL ASSETS:101435565768135
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities91075642
Accounts payable4532311
Accrued liabilities5544331
Employee-related liabilities    000
Other undisclosed current liabilities    (0)(0)(0)
Total current liabilities:91075642
Noncurrent Liabilities
Liabilities, other than long-term debt2222222
Deferred revenue and credits2222222
Total noncurrent liabilities:2222222
Total liabilities:101297753
Stockholders' equity
Stockholders' equity attributable to parent913146586976(59)
Common stock0000000
Additional paid in capital220147147146144142 
Accumulated other comprehensive income (loss)000(0)(0)  
Accumulated deficit(129)(116)(100)(87)(76)(67)(59)
Other undisclosed stockholders' equity      91
Total stockholders' equity:91314658697632
TOTAL LIABILITIES AND EQUITY:101435565768135

Income statement (P&L) ($ in millions)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Operating expenses(13)(16)(13)(11)(9)(8)(3)
Operating loss:(13)(16)(13)(11)(9)(8)(3)
Nonoperating income
(Investment Income, Nonoperating)
0000000
Net loss attributable to parent:(13)(16)(13)(11)(9)(8)(3)
Other undisclosed net loss available to common stockholders, basic   (13)   
Net loss available to common stockholders, basic:(13)(16)(13)(24)(9)(8)(3)
Other undisclosed net income (loss) available to common stockholders, diluted   13 (3)(4)
Net loss available to common stockholders, diluted:(13)(16)(13)(11)(9)(11)(7)

Comprehensive Income ($ in millions)

9/30/2016
Q3
6/30/2016
Q2
3/31/2016
Q1
12/31/2015
Q4
9/30/2015
Q3
6/30/2015
Q2
3/31/2015
Q1
Net loss:(13)(16)(13)(11)(9)(8)(3)
Other undisclosed comprehensive loss   (0)   
Comprehensive loss:(13)(16)(13)(11)(9)(8)(3)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)008(0)  
Comprehensive loss, net of tax, attributable to parent:(13)(16)(13)(4)(9)(8)(3)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: